<DOC>
	<DOCNO>NCT02215031</DOCNO>
	<brief_summary>Study investigate safety , tolerability , pharmacokinetics BI 44370 BS solution intravenous ( i.v . ) infusion</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Intravenous Doses BI 44370 BS Solution Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male accord follow criterion base upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) , Respiratory Rate ( RR ) body temperature ) , 12lead ECG , clinical laboratory test Age 21 50 year inclusive Body Mass Index ( BMI ) 18.5 29.9 kg/m2 inclusive Signed date write informed consent prior admission study accordance Good Clinical Practice German law Any find medical examination ( include BP , PR , RR , body temperature ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Not willing use adequate contraception ( condom use plus another form contraception , e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole study period time first intake study drug three month last intake</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>